Granted Patent
B2
US 12,496,342 · App. 18/512,759 · Granted Dec 16, 2025
Anti-CCR8 antibodies and uses thereof
Inventors:
Pamela M. Holland (Belmont, MA); Andrew Lake (Westwood, MA); Austin Dulak (Reading, MA); Ernest Smith (Rochester, NY); Maria Scrivens (Cambridge, NY); Caroline Harvey (Rochester, NY); Renee Kirk (Rochester, NY); Leslie Balch (Rochester, NY); Sonia Das (Cambridge, MA); Christopher Converse Wells (Cambridge, MA)
Assignee:
Vaccinex, Inc.
A61K39/39541A61K47/6849A61P35/00C07K16/2866C07K2317/31C07K2317/41C07K2317/622C07K2317/732C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.
Claims (33)
1 . A method of treating a subject having a tumor comprising administering to the subject an antibody or an antigen-binding portion thereof comprising a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 41 and comprising a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 43.
2 . The method of claim 1 , wherein the antibody or an antigen-binding portion thereof is afucosylated.
3 . The method of claim 1 , wherein the antibody or the antigen-binding portion thereof comprises an IgG1 Fc domain.
4 . The method of claim 1 , wherein the antibody or an antigen-binding portion thereof is administered as part of an immunoconjugate.
5 . The method of claim 4 , wherein the immunoconjugate is an antibody-drug conjugate.
6 . The method of claim 1 , wherein the antibody or an antigen-binding portion thereof is administered as part of a chimeric antigen receptor (CAR).
7 . The method of claim 1 , wherein the antibody or an antigen-binding portion thereof is administered as part of a T cell receptor (TCR).
8 . The method of claim 1 , wherein the tumor is selected from Kaposi's sarcoma, leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblasts promyelocyte myelomonocytic monocytic erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, primary central nervous system lymphoma, Burkitt's lymphoma and marginal zone B cell lymphoma, Polycythemia vera Lymphoma, Hodgkin's disease, non-Hodgkin's disease, multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, solid tumors, sarcomas, and carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chrondrosarcoma, osteogenic sarcoma, osteosarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon sarcoma, colorectal carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma (HCC), hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, uterine cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, retinoblastoma, nasopharyngeal carcinoma, esophageal carcinoma, basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain and central nervous system (CNS) cancer, cervical cancer, choriocarcinoma, colorectal cancers, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer, intraepithelial neoplasm, kidney cancer, larynx cancer, liver cancer, lung cancer (small cell, large cell), melanoma, neuroblastoma; oral cavity cancer (for example lip, tongue, mouth and pharynx), ovarian cancer, pancreatic cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer; cancer of the respiratory system, sarcoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, and cancer of the urinary system, or a combination thereof.
9 . The method of claim 1 , wherein the tumor is refractory or relapsed.
10 . The method of claim 1 , wherein the tumor is advanced, locally advanced, or metastatic.
11 . The method of claim 1 , further comprising administering an additional anticancer agent.
12 . The method of claim 11 , wherein the additional anticancer agent is a small molecule, a polypeptide, a radiation therapy, a surgery, or a combination thereof.
13 . The method of claim 11 , wherein the additional anticancer agent comprises a chemotherapy.
14 . The method of claim 13 , wherein the chemotherapy comprises a platinum-based chemotherapy.
15 . The method of claim 11 , wherein the additional anticancer agent comprises a PD-1 antagonist, a PD-L1 inhibitor, a TIM-3 inhibitor, a LAG-3 inhibitor, a TIGIT inhibitor, a CD112R inhibitor, a TAM inhibitor, a STING agonist, a 4-1BB agonist, a CCL22 inhibitor, an agent that induces NK cell activation or a combination thereof.
16 . The method of claim 11 , wherein the additional anticancer agent comprises a PD-1 antagonist.
17 . The method of claim 16 , wherein the PD-1 antagonist is selected from the group consisting of PDR001, nivolumab, pembrolizumab, pidilizumab, MEDI0680, REGN2810, TSR-042, PF-06801591, and AMP-224.
18 . The method of claim 11 , wherein the additional anticancer agent comprises a PD-L1 inhibitor.
19 . The method of claim 18 , wherein the PD-L1 inhibitor is selected from the group consisting of FAZ053, Atezolizumab, Avelumab, Durvalumab, and BMS-936559.
20 . The method of claim 11 , wherein the additional anticancer agent is Sunitinib, Cabozantinib, Axitinib, Lenvatinib, Everolimus, Bevacizumab, epacadostat, NKTR-214, Tivozanib, abexinostat, Ipilimumab, tremelimumab, Pazopanib, Sorafenib, Temsirolimus, Ramucirumab, niraparib, savolitinib, vorolanib (X-82), Regorafenib, Donafenib, Camrelizumab, pexastimogene devacirepvec, Ramucirumab, apatinib, encapsulated doxorubicin, Tivantinib, ADI-PEG 20, binimetinib, apatinib mesylate, nintedanib, lirilumab, Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab, Cemiplimab-rwlc, tislelizumab, spartalizumab, or a combination thereof.
21 . The method of claim 11 , wherein the additional anticancer agent comprises a TIM-3 inhibitor.
22 . The method of claim 21 , wherein the TIM-3 inhibitor is MGB453 or TSR-022.
23 . The method of claim 11 , wherein the additional anticancer agent comprises a LAG-3 inhibitor.
24 . The method of claim 23 , wherein the LAG-3 inhibitor is selected from the group consisting of LAG525, BMS-986016, and TSR-033.
25 . The method of claim 11 , wherein the additional anticancer agent comprises a TIGIT inhibitor.
26 . The method of claim 11 , wherein the additional anticancer agent comprises a CD112R inhibitor.
27 . The method of claim 11 , wherein the additional anticancer agent comprises a TAM (Axl, Mer, Tyro) inhibitor.
28 . The method of claim 11 , wherein the additional anticancer agent comprises a 4-1BB agonist.
29 . The method of claim 11 , wherein the additional anticancer agent comprises a Tyrosine Kinase Inhibitor (TKI).
30 . The method of claim 11 , wherein the additional anticancer agent comprises a CCL2 inhibitor.
31 . The method of claim 1 , wherein the tumor is a head and neck cancer tumor.
32 . The method of claim 1 , wherein the tumor is a gastric cancer tumor.
33 . The method of claim 1 , wherein the tumor is a squamous cell carcinoma tumor.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 1, 2023
From: SMITH, ERNEST; SCRIVENS, MARIA; HARVEY, CARRIE; KIRK, RENEE; BALCH, LESLIE
To: VACCINEX INC.
Reel/Frame 065735/0749 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 1, 2023
From: HOLLAND, PAMELA M.; LAKE, ANDREW; DULAK, AUSTIN; DAS, SONIA G.; WELLS, CHRISTOPHER CONVERSE
To: SURFACE ONCOLOGY, INC.
Reel/Frame 065735/0771 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 1, 2023
From: SURFACE ONCOLOGY, INC.
To: VACCINEX INC.
Reel/Frame 065735/0782 →
Continuity (5)
Provisional Application
63198803
· Nov 13, 2020
Provisional Application
62985152
· Mar 4, 2020
Provisional Application
62957758
· Jan 6, 2020
References Cited (296)
US 3773919A
· Boswell et al.
· 1973
[cited by applicant]
US 4676980A
· Segal et al.
· 1987
[cited by applicant]
US 5223409A
· Ladner et al.
· 1993
[cited by applicant]
US 5403484A
· Ladner et al.
· 1995
[cited by applicant]
US 5427908A
· Dower et al.
· 1995
[cited by applicant]
US 5500362A
· Robinson et al.
· 1996
[cited by applicant]
US 5516637A
· Huang et al.
· 1996
[cited by applicant]
US 5571698A
· Ladner et al.
· 1996
[cited by applicant]
US 5580717A
· Dower et al.
· 1996
[cited by applicant]
US 5624821A
· Winter et al.
· 1997
[cited by applicant]
US 5648260A
· Winter et al.
· 1997
[cited by applicant]
US 5658727A
· Barbas et al.
· 1997
[cited by applicant]
US 5698426A
· Huse
· 1997
[cited by applicant]
US 5733743A
· Johnson et al.
· 1998
[cited by applicant]
US 5750753A
· Kimae et al.
· 1998
[cited by applicant]
US 5780225A
· Wigler et al.
· 1998
[cited by applicant]
US 5821047A
· Garrard et al.
· 1998
[cited by applicant]
US 5821337A
· Carter et al.
· 1998
[cited by applicant]
US 5969108A
· McCafferty et al.
· 1999
[cited by applicant]
US 6001329A
· Buchsbaum et al.
· 1999
[cited by applicant]
US 6005079A
· Casterman et al.
· 1999
[cited by applicant]
US 6194551B1
· Idusogie et al.
· 2001
[cited by applicant]
US 6300064B1
· Knappik et al.
· 2001
[cited by applicant]
US 6737056B1
· Presta
· 2004
[cited by applicant]
US 6933368B2
· Co et al.
· 2005
[cited by applicant]
US 6995259B1
· Vargeese et al.
· 2006
[cited by applicant]
US 7332581B2
· Presta
· 2008
[cited by applicant]
US 7371826B2
· Presta
· 2008
[cited by applicant]
EP 0058481A1
· 1982
[cited by applicant]
EP 0133988A2
· 1985
[cited by applicant]
EP 0088046B1
· 1987
[cited by applicant]
EP 0143949B1
· 1988
[cited by applicant]
EP 0036676B2
· 1990
[cited by applicant]
EP 3431105A1
· 2019
[cited by applicant]
WO WO9002809A1
· 1990
[cited by applicant]
WO WO9110737A1
· 1991
[cited by applicant]
WO WO9201047A1
· 1992
[cited by applicant]
WO WO9218619A1
· 1992
[cited by applicant]
WO WO9311236A1
· 1993
[cited by applicant]
WO WO9315722A1
· 1993
[cited by applicant]
WO WO9404678A1
· 1994
[cited by applicant]
WO WO9420069A1
· 1994
[cited by applicant]
WO WO9425591A1
· 1994
[cited by applicant]
WO WO9429351A2
· 1994
[cited by applicant]
WO WO9515982A2
· 1995
[cited by applicant]
WO WO9520401A1
· 1995
[cited by applicant]
WO WO9627011A1
· 1996
[cited by applicant]
WO WO9951642A1
· 1999
[cited by applicant]
WO WO2004056312A2
· 2004
[cited by applicant]
WO WO2005100402A1
· 2005
[cited by applicant]
WO WO2006029879A2
· 2006
[cited by applicant]
WO WO2007024715A2
· 2007
[cited by applicant]
WO WO2007044756A2
· 2007
[cited by applicant]
WO WO2008024188A2
· 2008
[cited by applicant]
WO WO2013131010A2
· 2013
[cited by applicant]
WO WO2015063187A1
· 2015
[cited by applicant]
WO WO2015103072A1
· 2015
[cited by applicant]
WO WO2018112032A1
· 2018
[cited by applicant]
WO 2019157098A1
· 2019
[cited by applicant]
WO WO2021142002A1
· 2021
[cited by applicant]
Saxenma et al (Advances in Therapeutic Fc Engineering—Modulation of IgG-Associated Effector Functions and Serum Half-life. Front Immunol. Dec. 12, 2016;7:580. doi: 10.3389/fimmu.2016.00580). (Year: 2016).
[cited by examiner]
Song et al (Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects. Acta Biomater. Mar. 2014;10(3): 1392-402. doi: 10.1016/j.actbio.2013.11.026. Epub Dec. 6…
[cited by examiner]
National Cancer Institute, The “Accidental” Cure-Platinum-based Treatment of Cancer: The Discovery of Cisplatin, retrieved from: https://www.cancer.gov/research/progress/discovery/cisplatin (posted May 30, 2014)) (Year:…
[cited by examiner]
Lipson et al (Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol. Aug. 2015;42(4):587-600. doi: 10.1053/j.seminoncol.2015.05.013. Epub Jun. 10, 2015) (Year: 2015).
[cited by examiner]
Shah et al (Product review on the Anti-PD-L1 antibody atezolizumab. Hum Vaccin Immunother. Feb. 1, 2018;14(2):269-276. doi: 10.1080/21645515.2017.1403694. Epub Dec. 20, 2017) (Year: 2017).
[cited by examiner]
Borate et al (Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) _ Blood _ American Society of Hema…
[cited by examiner]
Bristol-Myers Squibb Company (https://news.bms.com/news/details/2017/Anti-LAG-3-BMS-986016-in-Combination-with-Opdivo-nivolumab-Showed-Activity-in-Patients-with-Melanoma-Who-Were-Relapsed-or-Refractory-to-Anti-PD-1PD-L1…
[cited by examiner]
Dougall et al (TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. Mar. 2017;276(1):112-120. doi: 10.1111/imr.12518. (2017)). (Year: 2017).
[cited by examiner]
Zhu et al (Identification of CD112R as a novel checkpoint for human T cells, https://doi.org/10.1084/jem.20150785. (2016)) (Year: 2016).
[cited by examiner]
Uribe et al (The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer, https://doi.org/10.1371/journal.pone.0179979 (2017)) (Year: 2017).
[cited by examiner]
Bartkowiak et al (4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol. Jun. 8, 2015;5:117. doi: 10.3389/fonc.2015.00117). (Year: 2015).
[cited by examiner]
Tan et al (Targeting tumour microenvironment by tyrosine kinase inhibitor. Mol Cancer 17, 43 (2018). https://doi.org/10.1186/s12943-018-0800-6) (Year: 2018).
[cited by examiner]
Linehan et al (Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.. JCO 36, 92-92(2018); DOI:10.1200/JCO.201…
[cited by examiner]
Bates et al (Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. Dec. 1, 2006;24(34):5373-80. doi: 10.1200/JCO.2006.05.958…
[cited by examiner]
Examination Report dated Jan. 8, 2024 issued in corresponding Australian Patent Application No. 2021205877 (4 pages).
[cited by applicant]
Office Action dated Jan. 29, 2024 issued in corresponding Japanese Patent Application No. 2022-535120 and translation (10 pages).
[cited by applicant]
Communication dated Mar. 28, 2024 issued in corresponding European Patent Application No. 21 702 556.8 (9 pages).
[cited by applicant]
Akdis, M., et al., “T regulatory cells in allergy: Novel concepts in the pathogenesis, prevention, and treatment of allergic diseases,” J Allergy Clin Immunol 116(5):961-8, Elsevier, Netherlands (Nov. 2005).
[cited by applicant]
Altschul, S.F., et al., “Basic Local Alignment Search Tool,” Journal of Molecular Biology 215(3):403-410, Elsevier, United Kingdom (Oct. 1990).
[cited by applicant]
Altschul, S.F., et al., “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,” Nucleic Acids Research 25(17):3389-3402, Oxford University Press, United Kingdom (Sep. 1997).
[cited by applicant]
Ames, R.S., et al., “Conversion of Murine Fabs Isolated From a Combinatorial Phage Display Library to Full Length Immunoglobulins,” Journal of Immunological Methods 184(2):177-186, Elsevier, Netherlands (1995).
[cited by applicant]
Annunziato, F., et al., “Phenotype, Localization, and Mechanism of Suppression of CD4+ cd25+ Human Thymocytes,” J Exp Med 196(3):379-87, Rockefeller University Press, United States (Aug. 2002).
[cited by applicant]
Baldridge, J.R. and Crane, R.T., “Monophosphoryl Lipid A (MPL) Formulations for the Next Generation of Vaccines,” Methods, 19(1):103-107, Academic Press, United States (Sep. 1999).
[cited by applicant]
Barsheshet, Y., et al., “CCR8 + FOXp3 + T reg Cells as Master Drivers of Immune Regulation,” Proceedings of the National Academy of Sciences of the United States of America, 114(23):6086-6091, National Academy of Scienc…
[cited by applicant]
Batzer, M.A., et al., “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus,” Nucleic Acids Research 19(18):5081, Oxford University Press, United Kingdom (Sep. 1991).
[cited by applicant]
Berge, S.M., et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences 66(1):1-19, Elsevier, United States (Jan. 1977).
[cited by applicant]
Bhatt, D., et al., “STARTRAC analyses of scRNAseq data from tumor models reveal T cell dynamics and therapeutic targets,” J Exp Med 218(6):e20201329, Rockefeller University Press, United States (Jun. 2021).
[cited by applicant]
Bieg, S., et al., “Gad65 and Insulin B Chain Peptide (9-23) Are Not Primary Autoantigens in the Type 1 Diabetes Syndrome of the Bb Rat,” Autoimmunity 31(1):15-24, Taylor & Francis, United Kingdom (Jan. 1999).
[cited by applicant]
Bird, R.E., et al., “Single-chain Antigen-binding Proteins,” Science 242(4877):423-426, Association for the Advancement of Science, United States (Oct. 1988).
[cited by applicant]
Boder, E,T. and Wittrup, K,D., “Yeast Surface Display for Directed Evolution of Protein Expression, Affinity, and Stability,” Methods Enzymology, 328:430-444, Academic Press, United States (2000).
[cited by applicant]
Bos, P., et al., “Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy,” J Exp Med 210(11):2435-66, Rockefeller University Press, United States (Oct. 2013).
[cited by applicant]
Bournazos, S., et al., “The Role and Function of Fcγ Receptors on Myeloid Cells,” Microbiol Spectr 4(6):10, American Society for Microbiology, United States (Dec. 2016).
[cited by applicant]
Boutros, C., et al., “Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination,” Nat Rev Clin Oncol 13(8):473-86, Springer, Germany (Aug. 2016).
[cited by applicant]
Brahmer, J., et al., “Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer,” N Engl J Med 366(26):2455-65, Massachusetts Medical Society, United States (Jun. 2012).
[cited by applicant]
Brennan, M., et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science 229(4708):81-83, American Association for the Advancement of Science, United State…
[cited by applicant]
Brinkmann, U., et al., “Phage Display of Disulfide-stabilized Fv Fragments,” Journal of Immunological Methods 182(1):41-50, Elsevier, Netherlands (1995).
[cited by applicant]
Bruggemann, M., et al., “Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies,” The Journal of Experimental Medicine, 166:1351-1361, Rockefeller University Press, Unit…
[cited by applicant]
Burton, D.R. and Barbas, C.F. 3rd., “Human Antibodies From Combinatorial Libraries,” Advances in Immunology 57:191-280, Academic Press, United States (1994).
[cited by applicant]
Cambay, F., et al., “Impact of IgG1 N-glycosylation on their interaction with Fc gamma receptors,” Curr Res Immunol 1:23-37, Elsevier, Netherlands (Jun. 2020).
[cited by applicant]
Campbell, J., et al., “Fc-optimized anti-CCR8 antibody depletes regulatory T cells in human tumor models,” Cancer Res 81(11):2983-2994, American Association for Cancer Research, United States (Jun. 2021).
[cited by applicant]
Canfield, S.M., et al., “The Binding Affinity of Human Igg for Its High Affinity Fc Receptor Is Determined by Multiple Amino Acids in the Ch2 Domain and Is Modulated by the Hinge Region,” Journal of Experimental Medicin…
[cited by applicant]
Cao, W., et al., “CD83 is preformed inside monocytes, macrophages and dendritic cells, but it is only stably expressed on activated dendritic cells,” Biochem J 385(Pt 1):85-93, Biochemical Society (Jan. 2005).
[cited by applicant]
Caron, P.C., et al., “Engineered Humanized Dimeric Forms of Igg Are More Effective Antibodies,” Journal of Experimental Medicine 176(4):1191-1195, Rockefeller University Press, United States (Oct. 1992).
[cited by applicant]
Chasteen, L., et al.,, “Eliminating Helper Phage From Phage Display,” Nucleic Acids Research, 34(21):e145, Oxford University Press, United Kingdom (2006).
[cited by applicant]
Chensue, S.W., et al., “Aberrant In Vivo T Helper Type 2 Cell Response and Impaired Eosinophil Recruitment in CC Chemokine Receptor 8 Knockout Mice,” J Exp Med 193(5):573-84, Rockefeller University Press, United States …
[cited by applicant]
Cheung, R.C., et al., “Epitope-specific Antibody Response to the Surface Antigen of Duck Hepatitis B Virus in Infected Ducks,” Virology 176(2):546-552, Academic Press, United States (1990).
[cited by applicant]
Chung, C.D., et al., “CCR8 Is Not Essential for the Development of Inflammation in a Mouse Model of Allergic Airway Disease,” J Immunol 170(1):581-7, American Association of Immunologists, United States (Jan. 2003).
[cited by applicant]
Clynes, R., et al., “Fc Receptors Are Required in Passive and Active Immunity to Melanoma,” Proceedings of the National Academy of Sciences of the USA 95(2):652-656, National Academy of Sciences, United States (1998).
[cited by applicant]
Co, M.S., et al., “Genetically Engineered Deglycosylation of the Variable Domain Increases the Affinity of an Anti-CD33 Monoclonal Antibody,” Molecular Immunology 30(15):1361-1367, Pergamon Press, United Kingdom (1993).
[cited by applicant]
Cornelis, P., et al., “Expressing Genes in Different
[cited by applicant]
Cragg, M.S, and Glennie, M.J., “Antibody Specificity Controls in Vivo Effector Mechanisms of Anti-CD20 Reagents,” Blood, 103:2738-2743, Elsevier, United States (Apr. 2004).
[cited by applicant]
Cragg, M.S., et al., “Complement-mediated Lysis by Anti-CD20 mAb Correlates with Segregation into Lipid Rafts,” Blood 101(3):1045-1052, American Society of Hematology, United States (Feb. 2003).
[cited by applicant]
Das, S., et al., “Immune-related adverse events and antitumor efficacy of immune checkpoint inhibitors,” J Immunother Cancer 7(1):306, BMJ Publishing Group Ltd and Society for Immunotherapy of Cancer, United Kingdom (No…
[cited by applicant]
De Simone, M., et al., “Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells,” Immunity 45(5):1135-1147, Cell Press, United States (Nov. 2016).
[cited by applicant]
Deans, R.J., et al., “Expression of an Immunoglobulin Heavy Chain Gene Transfected Into Lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America, 81(5):1292-1296, National Academy of…
[cited by applicant]
Delacher, M., et al., : Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells, Immunity 54(4):702-720, Cell Press, United States (Apr. 2021).
[cited by applicant]
Demengeot, J., et al., “Regulatory T cells in microbial infection,” Springer Semin Immunopathol 28(1):41-50, Springer, Germany (Aug. 2006).
[cited by applicant]
Domingues-Villar, M., et al., “Regulatory T cells in autoimmune disease,” Nat Immunol 19(7):665-673, Springer, Germany (Jul. 2018).
[cited by applicant]
Duncan, A,R. and Winter, G., “The Binding Site for C1q on IgG,” Nature, 332(6166):738-740, Nature Publishing Group, United Kingdom (Apr. 1988).
[cited by applicant]
Ebert, L., et al., “Homing and Function of Human Skin gammadelta T Cells and NK Cells: Relevance for Tumor Surveillance,” J Immunol 176(7):4331-6, American Association of Immunologists, United States (Apr. 2006).
[cited by applicant]
Eisenhauer, E.A., et al., “New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1),” Eur J Cancer 45(2):228-47, Elsevier, Netherlands (Jan. 2009).
[cited by applicant]
Engberg, J., et al., “Phage-Display Libraries of Murine and Human Antibody Fab Fragments,” Methods in Molecular Biology, 51:355-376, Humana Press, United States (1995).
[cited by applicant]
Eppstein, D.A., et al., “Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor,” Proceedings of the National Academy of Sciences 82(11):3688-3692, National Academy …
[cited by applicant]
Etz, H., et al., “Bacterial Phage Receptors, Versatile Tools for Display of Polypeptides on the Cell Surface,” Journal of Bacteriology 183(23):6924-6935, American Society for Microbiology, United States (Dec. 2001).
[cited by applicant]
Falconer, D., et al., “Antibody fucosylation lowers FcγRIIIa/CD16a affinity by limiting the conformations sampled by the N162-glycan,” ACS Chem Biol 13(8):2179-2189, American Chemical Society, United States (Aug. 2018).
[cited by applicant]
Fu., J., et al., “Increased Regulatory T Cells Correlate With CD8 T-Cell Impairment and Poor Survival in Hepatocellular Carcinoma Patients,” Gastroenterology 132(7):2328-39, Elsevier, Netherlands (Jun. 2007).
[cited by applicant]
Gazzano-Santoro, H., et al., “A Non-Radioactive Complement-dependent Cytotoxicity Assay for Anti-CD20 Monoclonal Antibody,” Journal of Immunological Methods, 202:163-171, Elsevier, Netherlands (Mar. 1997).
[cited by applicant]
Goldberg, B., et al., “Antibody-mediated complement activation in pathology and protection,” Immunol Cell Biol 98(4):305-317, Wiley, United States (Apr. 2020).
[cited by applicant]
Goya, I., et al., “Absence of CCR8 Does Not Impair the Response to Ovalbumin-Induced Allergic Airway Disease,” J Immunol 170(4):2138-46, American Association of Immunologists, United States (Feb. 2003).
[cited by applicant]
Grabherr, R and Ernst, W., “The Baculovirus Expression System as a Tool for Generating Diversity by Viral Surface Display,” Combinatorial Chemistry & High Throughput Screening, 4(2):185-192, Bentham Science Publishers, …
[cited by applicant]
Green, J., et al., “A nonimmune function of T cells in promoting lung tumor progression,” J Exp Med 214(12):3565-3575, Rockefeller University Press, United States (Dec. 2017).
[cited by applicant]
Gruber, M., et al., “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in
[cited by applicant]
Gupta, R.K and Siber, G.R., “Adjuvants for Human Vaccines—current Status, Problems and Future Prospects,” Vaccine, 13(14):1263-1276, Elsevier Science, Netherlands (Oct. 1995).
[cited by applicant]
Guyer, R.L., et al., “Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors,” Journal of Immunology, 117(2):587-93, American Association of Immunologists, United States (Aug. 1976).
[cited by applicant]
Hanes, J., et al., “Picomolar Affinity Antibodies from a Fully Synthetic Naive Library Selected and Evolved by Ribosome Display,” Nature Biotechnology 18(12):1287-1292, Nature America Publishing, United States (Dec. 200…
[cited by applicant]
Harding, F.A. and Lonberg, N., “Class Switching in Human Immunoglobulin Transgenic Mice,” Annals of the New York Academy of Sciences 764:536-546, The Academy, United States (1995).
[cited by applicant]
Hellstrom, I., et al., “ Strong Antitumor Activities of IgG3 Antibodies to a Human Melanoma-Associated Ganglioside,” Proceedings of the National Academy of Sciences of the United States of America, 82:1499-1502, Nationa…
[cited by applicant]
Hellstrom, I., et al., “Antitumor Effects of L6, An IgG2a Antibody That Reacts With Most Human Carcinomas,” Proceedings of the National Academy of Sciences of the United States of America, 83:7059-7063. National Academy…
[cited by applicant]
Hodi, F., et al., “Improved Survival with Ipilimumab in Patients with Metastatic Melanoma,” N Engl J Med 363(8):711-23, Massachusetts Medical Society, United States (Aug. 2010).
[cited by applicant]
Hoelzinger, D.B., et al., Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses, Journal of Immunology, 184(12):6833-6842, American Association …
[cited by applicant]
Holliger, P., et al., “Diabodies: Small Bivalent and Bispecific Antibody Fragments,” Proceedings of the National Academy of Sciences of the United States of America 90(14):6444-6448, National Academy of Sciences, United…
[cited by applicant]
Hoogenboom, H.R., et al., “Designing and Optimizing Library Selection Strategies for Generating High-affinity Antibodies,” Trends in Biotechnology 15(2):62-70, Elsevier Science, United Kingdom (1997).
[cited by applicant]
Hou, J. and Zhan, H., “Expression of Active Thrombopoietin and Identification of Its Key Residues Responsible for Receptor Binding”, Cytokine 10(5):319-330, Elsevier Science Ltd, United Kingdom (May 1998).
[cited by applicant]
Houdebine, L.M., “Antibody Manufacture in Transgenic Animals and Comparisons With Other Systems”, Current Opinion in Biotechnology 13(6):625-629, Elsevier, United Kingdom (Dec. 2002).
[cited by applicant]
Huang, S., et al., “Development of Hybrid Viral Vectors for Gene Therapy,” Biotechnology Advances, 31(2):208-223, Elsevier Science, United Kingdom (Mar.-Apr. 2013).
[cited by applicant]
Hudson, P.J. and Kortt, A.A., “High Avidity scFv Multimers; Diabodies and Triabodies,” Journal of Immunological Methods 231(1-2):177-189, Elsevier, Netherlands (Dec. 1999).
[cited by applicant]
Huston, J.S., et al., “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in
[cited by applicant]
Idusogie, E.E., et al., “Mapping of the C1q Binding Site on Rituxan, A Chimeric Antibody with a Human IgG1 Fc,” The Journal of Immunology 164(8):4178-4184, American Association of Immunologists, United States (2000).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/012329, European Patent Office, Netherlands, mailed on May 4, 2021, 12 pages.
[cited by applicant]
Islam, S., et al., “Identification of human CCR8 as a CCL18 receptor,” J Exp Med 210(10):1889-98, Rockefeller University Press, United States (Sep. 2013).
[cited by applicant]
Jhunjhunwala, S., et al., “Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion,” Nat Rev Cancer 21(5):298-312, Springer, Germany (May 2021).
[cited by applicant]
Jo, M., et al., “Engineering Therapeutic Antibodies Targeting G-protein-coupled Receptors,” Experimental & Molecular Medicine, 48(2):e207, Nature Publishing Group, United States (Feb. 2016).
[cited by applicant]
Johnson, D.A., “3-O-Desacyl monophosphoryl lipid A Derivatives: Synthesis and Immunostimulant Activities,” Journal of Medicinal Chemistry 42(22):4640-4649, American Chemical Society, United States (Nov. 1999).
[cited by applicant]
Kabat, E.A., et al., “Sequences of proteins of immunological interest,” 5th Edition, NIH publication No. 91-3242, U.S. Department of Public Health and Human Services, National Institutes of Health, United States (1991).
[cited by applicant]
Kang, L., et al., “CCR8 Signaling via CCL1 Regulates Responses of Intestinal IFN-g Producing Innate Lymphoid Cells and Protects From Experimental Colitis,” Front Immunol 11:609400, Frontiers Media S.A., Switzerland (Feb…
[cited by applicant]
Kaszubska, W., et al., “Expression, Purification, and Characterization of Human Recombinant Thrombopoietin in Chinese Hamster Ovary Cells,” Protein Expression and Purification 18(2):213-220, Academic Press, United State…
[cited by applicant]
Kettleborough, C.A., et al., “Isolation of Tumor Cell-specific Single-chain Fv From Immunized Mice Using Phage-antibody Libraries and the Re-construction of Whole Antibodies From These Antibody Fragments,” European Jour…
[cited by applicant]
Kidani, Y., et al., “CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory,” Proc Natl Acad Sci U S A 119(7):e2114282119, National Academ…
[cited by applicant]
Kieke, M.C., et al., “Isolation of Anti-T Cell Receptor ScFv Mutants by Yeast Surface Display”, Protein Engineering, 10(11):1303-1310, Oxford University Press, United Kingdom (Nov. 1997).
[cited by applicant]
Kim, J., et al., “Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice,” Nat Immunol 8(2):191-7, Springer, Germany (Feb. 2007).
[cited by applicant]
Kim, J.K., et al., “Identifying Amino Acid Residues that Influence Plasma Clearance of Murine IgG1 Fragments by Site-Directed Mutagenesis,” European Journal of Immunology 24(3):542-548, Wiley-VCH, Germany (Mar. 1994).
[cited by applicant]
Kinstler, O., et al., “Mono-N-terminal Poly(Ethylene Glycol)-protein Conjugates,” Advanced Drug Delivery Reviews 54(4):477-485, Elsevier Science Publishers, Netherlands (Jun. 2002).
[cited by applicant]
Kirkland, T.N., et al., “Analysis of the Fine Specificity and Cross-reactivity of Monoclonal Anti-lipid A Antibodies,” Journal of Microbiology 137(11):3614-3619, Microbiological Society of Korea, Korea (1986).
[cited by applicant]
Klemm, P. and Schembri, M, A., “Fimbrial Surface Display Systems in Bacteria: From Vaccines to Random Libraries,” Microbiology (Reading), 146(12):3025-3032, Microbiology Society, United Kingdom (Dec. 2000).
[cited by applicant]
Kostelny, S.A., et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553, American Association of Immunologists, United States (Mar. 1992).
[cited by applicant]
Kuik-Romeijn, P, V., et al., “Expression of a Functional Mouse-human Chimeric Anti-cd19 Antibody in the Milk of Transgenic Mice,” Transgenic Res, 9(2):155-159, Kluwer Academic Publishers, Netherlands (Apr. 2000).
[cited by applicant]
Lan, R., et al., “Highly selective anti-CCR8 antibody-mediated depletion of regulatory T cells leads to potent antitumor activity alone and in combination with anti-PD-1 in preclinical models,” Abstract 6694, Cancer Res…
[cited by applicant]
Langer, R., et al., “Biocompatibility of Polymeric Delivery Systems for Macromolecules,” Journal of Biomedical Materials Research 15(2):267-277, John Wiley & Sons, Inc., United States (1981).
[cited by applicant]
Langer, R.,, “Controlled release of macromolecules,” Chem. Tech 12:98-105, American Chemical Society, United States (1982).
[cited by applicant]
Laursen, N., et al., “Functional and Structural Characterization of a Potent Clq Inhibitor Targeting the Classical Pathway of the Complement System,” Front Immunol 11:1504, Frontiers Media S.A., Switzerland (Jul. 2020).
[cited by applicant]
Lee, D., et al., “ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells,” Biol Blood Marrow Transplant 25(4):625-638, Elsevier, Netherlands (Apr. 2019).
[cited by applicant]
Lee, L.S., et al., “Prolonged Circulating Lives of Single-chain Fv Proteins Conjugated With Polyethylene Glycol: a Comparison of Conjugation Chemistries and Compounds,” Bioconjugate Chemistry, 10(6):973-981, American Ch…
[cited by applicant]
Lin, W., et al., “Fc-dependent expression of CD137 on human NK cells: insights into ‘agonistic’ effects of anti-CD 137 monoclonal antibodies,” Blood 112(3):699-707, American Society of Hematology, United States (Aug. 20…
[cited by applicant]
Liu, S., and Yuan, Y., “Bayesian Optimal Interval Designs for Phase I Clinical Trials,” Journal of the Royal Statistical Society 64(3):507-523, Wiley, United States (2014).
[cited by applicant]
Lodmell, D.L., et al., “DNA Vaccination of Mice Against Rabies Virus: Effects of the Rroute of Vaccination and The Adjuvant Monophosphoryl Lipid A (MPL),” Vaccine, 18(11-12):1059-1066, Elsevier Science, Netherlands (Jan…
[cited by applicant]
Lonberg, N. and Huszar, D., “Human Antibodies from Transgenic Mice,” International Reviews of Immunology 13(1):65-93, Informa Healthcare, United Kingdom (1995).
[cited by applicant]
Lonberg, N., “Handbook of Experimental Pharmacology,” The Pharmacology of Monoclonal Antibodies 113:49-101, (1994).
[cited by applicant]
Lonberg, N., “Human Antibodies From Transgenic Animals,” Nature Biotechnology, 23(9):1117-1125, Nature America Publishing, United States (Sep. 2005).
[cited by applicant]
Lonberg, N., et al., “Antigen-specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications,” Nature 368(6474):856-859, Nature Publishing Group, United States (Apr. 1994).
[cited by applicant]
Lusky, M. and Botchan, M., “Inhibition of Sv40 Replication in Simian Cells by Specific Pbr322 Dna Sequences,” Nature, 293(5827):79-81, Nature Publishing Group, United Kingdom (Sep. 1981).
[cited by applicant]
Magnuson, A., et al., “Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types,” Proc Natl Acad Sci U S A 115(45):E10672-E10681, National Academy of …
[cited by applicant]
McCafferty, J., et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature 348(6301):552-554, Nature Publishing Group, United Kingdom (Dec. 1990).
[cited by applicant]
McCarthy et al., “Alterting the fine specificity of an anti-Legionella single chain antibody by a single amino acid insertion”, Journal of Immunological Methods 251 (2001) 137-149.
[cited by applicant]
Mccully, M., et al., “CCR8 Expression Defines Tissue-Resident Memory T Cells in Human Skin,” J Immunol 200:1639-1650, American Association of Immunologists, United States (Mar. 2018).
[cited by applicant]
Mccully, M., et al., “Epidermis instructs skin homing receptor expression in human T cells,” Blood 120(23):4591-8, American Society of Hematology, United States (Nov. 2012).
[cited by applicant]
Mccully, M., et al., “Skin Metabolites Define a New Paradigm in the Localization of Skin Tropic Memory T Cells,” J Immunol 195(1):96-104, American Association of Immunologists, United States (Jul. 2015).
[cited by applicant]
Merle, N., et al., “Complement system part i—molecular mechanisms of activation and regulation,” Front Immunol 2;6:262, Frontiers Media S.A., Switzerland (Jun. 2015).
[cited by applicant]
Merz, D.C., et al., “Generating a Phage Display Antibody Library Against an Identified Neuron,” Journal of Neuroscience Methods, 62(1-2):213-219, Elsevier/North-Holland Biomedical Press, Netherlands (Nov. 1995).
[cited by applicant]
Michael, S, I., et al., “Addition of a Short Peptide Ligand to the Adenovirus Fiber Protein,” Gene Ther, 2(9):660-668, Nature Publishing Group, United Kingdom (Nov. 1995).
[cited by applicant]
Mikhak, Z., et al., “Contribution of CCR4 and CCR8 to antigen-specific Th2 cell trafficking in allergic pulmonary inflammation,” J Allergy Clin Immunol 123(1):67-73, Elsevier, Netherlands (Jan. 2009).
[cited by applicant]
Milstein, C. and Cuello, A.C., “Hybrid Hybridomas and their Use in Immunohistochemistry,” Nature 305(5934):537-540, Nature Publishing Group, United Kingdom (Oct. 1983).
[cited by applicant]
Misumi, T., et al., “Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer,” PLoS One 13(10):e0204880, PLOS, United States (Oct. 2018).
[cited by applicant]
Moldenhauer, G., et al., “Identity of HML-1 Antigen on Intestinal Intraepithelial T Cells and of B-ly7 Antigen on Hairy Cell Leukaemia,” Scandinavian Journal of Immunology 32(2):77-82, Blackwell Scientific Publications,…
[cited by applicant]
Morel, G.A., et al., “Monoclonal Antibodies to Bovine Serum Albumin: Affinity and Specificity Determinations,” Molecular Immunology 25(1):7-15, Pergamon Press, United Kingdom (1988).
[cited by applicant]
Moser, B., “Chemokine Receptor-Targeted Therapies: Special Case for CCR8,” Cancers (Basel) 14(3):511, MDPI, Switzerland (Jan. 2022).
[cited by applicant]
Mueller, J.P., et al., “Humanized Porcine VCAM-specific Monoclonal Antibodies With Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells,” Molecular Immunology 34(6):441-452, Perga…
[cited by applicant]
Muenst, S., et al., “The immune system and cancer evasion strategies: therapeutic concepts,” J Intern Med 279(6):541-62, Wiley, United States (Jun. 2016).
[cited by applicant]
Mulligan, R.C. and Berg, P., “Selection for Animal Cells that Express the
[cited by applicant]
Mutalithas, K., et al., “Expression of CCR8 is increased in asthma,” Clin Exp Allergy 40(8):1175-85, Wiley, United States (Aug. 2010).
[cited by applicant]
Muyldermans, S., et al., “Recognition of Antigens by Single-Domain Antibody Fragments: the Superfluous Luxury of Paired Domains,” Trends in Biochemical Sciences 26(4):230-235, Elsevier Trends Journals, United Kingdom (A…
[cited by applicant]
Myers, E.W. and Miller, W., “Optimal Alignments in Linear Space,” Computer Applications in the Biosciences 4(1):11-17, Oxford University Press, United Kingdom (Mar. 1988).
[cited by applicant]
Needleman, S.B. and Wunsch, C.D., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,” Journal of Molecular Biology 48(3):443-453, Academic Press, United Kingdom (Mar.…
[cited by applicant]
Neelapu, S., et al., “Chimeric antigen receptor T-cell therapy—assessment and management of toxicities” Nat Rev Clin Oncol 15(1):47-62, Springer, Germany (Jan. 2018).
[cited by applicant]
Niro R.D., et al., “Characterizing Monoclonal Antibody Epitopes by Filtered Gene Fragment Phage Display,” The American Journal of Pathology, 388(Pt 3):889-894, Elsevier, United States (Jun. 2005).
[cited by applicant]
Nuttall, S.D., et al., “Immunoglobulin VH Domains and Beyond: Design and Selection of Single-domain Binding and Targeting Reagents,” Current Pharmaceutical Biotechnology 1(3):253-263, Bentham Science Publishers, Netherl…
[cited by applicant]
Ohtsuka, E., et al., “An Alternative Approach to Deoxyoligonucleotides as Hybridization Probes by Insertion of Deoxyinosine at Ambiguous Codon Positions,” The Journal of Biological Chemistry 260(5):2605-2608, Elsevier I…
[cited by applicant]
Oken, M., et al., “Toxicity and response criteria of the Eastern Cooperative Oncology Group,” Am J Clin Oncol 5(6):649-55, American Society of Clinical Oncology, United States (Dec. 1982).
[cited by applicant]
Onda, M., et al., “Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity,” Proc Natl Acad Sci U S A 116(10):4575-4582, National Academy of Scienc…
[cited by applicant]
Panina-Bordignon, P., et al., “The C—C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics,” J Clin Invest 107(11):1357-64, American Society for Clinical Investigation, Uni…
[cited by applicant]
Pavisic, R., et al., “Recombinant Human Granulocyte Colony Stimulating Factor Pre-screening and Screening of Stabilizing Carbohydrates and Polyols,” International Journal of Pharmaceutics, 387(1-2):110-119, Amsterdam, E…
[cited by applicant]
Pearson, W.R. and Lipman, D.J., “Improved Tools for Biological Sequence Comparison,” Proceedings of the National Academy of Sciences of the United States of America 85(8):2444-2448, National Academy of Sciences, United …
[cited by applicant]
Pereboev, A., et al., “Phage Display of Adenovirus Type 5 Fiber Knob as a Tool for Specific Ligand Selection and Validation,” Journal of Virology, 75(15):7107-7113, American Society For Microbiology, United States (Aug.…
[cited by applicant]
Persic, L., et al., “An Integrated Vector System for the Eukaryotic Expression of Antibodies or Their Fragments After Selection From Phage Display Libraries,” Gene 187(1):9-18, Elsevier/North-Holland, Netherlands (1997).
[cited by applicant]
Petersen, R., et al., “Tumor Infiltrating FOXP31 Regulatory T-cells Are Associated With Recurrence in Pathologic Stage I NSCLC Patients,” Cancer 107(12):2866-72, Wiley, United States (Dec. 2006).
[cited by applicant]
Petkova, S.B., et al., “Enhanced Half-Life of Genetically Engineered Human IgG1 Antibodies in a Humanized FcRn Mouse Model: Potential Application in Humorally Mediated Autoimmune Disease,” International Immunology 18(12…
[cited by applicant]
Plitas, G., et al., “Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer,” Immunity 45(5):1122-1134, Cell Press, United States (Nov. 2016).
[cited by applicant]
Plitas, G., et al., “Regulatory T Cells in Cancer,” Annu Rev Cancer Biol 4:459-577, Annual Reviews Inc., United States (Mar. 2020).
[cited by applicant]
Poljak, R.J., “Production and Structure of Diabodies,” Structure 2(12):1121-1123, Cell Press, United States (1994).
[cited by applicant]
Pollock, D., et al., “Transgenic milk as a method for the production of recombinant antibodies”, Journal of Immunological Methods 231: 147-157, Elsevier, Netherlands (1999).
[cited by applicant]
Ravetch, J.V. and Kinet, J.P., “Fc Receptors,” Annual Review of Immunology 9:457-492, Annual Reviews Inc, United States (1991).
[cited by applicant]
Ricard, M., “Survey of CCR8 expression in normal human tissues by immunohistochemistry,” Report SRF114-R0014, 34 pages, Surface Oncology, Inc. (Jun. 2022).
[cited by applicant]
Riechmann, L. and Muyldermans, S., “Single Domain Antibodies: Comparison of Camel VH and Camelised Human VH Domains,” Journal of Immunological Methods 231(1-2):25-38, Elsevier, Netherlands (Dec. 1999).
[cited by applicant]
Robert, C., et al., “A decade of immune-checkpoint inhibitors in cancer therapy,” Nat Commun 11(1):3801, Springer, Germany (Jul. 2020).
[cited by applicant]
Roberts, M.J., et al., “Chemistry for Peptide and Protein Pegylation,” Advanced Drug Delivery Reviews, 54(4):459-476, Elsevier Science Publishers, B.V., Netherlands (Jun. 2002).
[cited by applicant]
Rogers, B.E., et al., “Localization of Iodine-125-mip-des-met14-bombesin (7-13)nh2 in Ovarian Carcinoma Induced to Express the Gastrin Releasing Peptide Receptor by Adenoviral Vector-mediated Gene Transfer,” The Journal…
[cited by applicant]
Romano, E., et al., “Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients,” Proc Natl Acad Sci USA 112(19):6140-5, National Academy of Sciences (Ma…
[cited by applicant]
Rondon, I.J. and Marasco, W.A., “Intracellular Antibodies (Intrabodies) for Gene Therapy of Infectious Diseases,” Annual Review of Microbiology, 51(1):257-283, Annual Reviews, United States (1997).
[cited by applicant]
Roos, R., et al., “Identification of CCR8, the Receptor for the Human CC Chemokine I-309” J Exp Med 186(1):165-70, Rockefeller University Press, United States (Jul. 1997).
[cited by applicant]
Rossolini, G.M., et al., “Use of Deoxyinosine-Containing Primers vs Degenerate Primers for Polymerase Chain Reaction Based on Ambiguous Sequence Information,” Molecular and Cellular Probes 8(2):91-98, Academic Press, Un…
[cited by applicant]
Sakaguchi, S., et al., “Regulatory T Cells and Human Disease,” Annu Rev Immunol 38:541-566, Annual Reviews Inc., United States (Apr. 2020).
[cited by applicant]
Sarver, N., et al., “Transformation and Replication in Mouse Cells of a Bovine Papillomavirus--pml2 Plasmid Vector That Can Be Rescued in Bacteria,” Proceedings of the National Academy of Sciences of the United States o…
[cited by applicant]
Schaerli, P., et al., “A Skin-selective Homing Mechanism for Human Immune Surveillance T Cells,” J Exp Med 199(9):1265-75, Rockefeller University Press, United States (May 2004).
[cited by applicant]
Schaffitzel, C., et al., “Ribosome Display: An in Vitro Method for Selection and Evolution of Antibodies From Libraries,” Journal of Immunological Methods 231(1-2):119-135, Elsevier, Netherlands (Dec. 1999).
[cited by applicant]
Schoonbroodt, S., et al., “Oligonucleotide-Assisted Cleavage and Ligation: A Novel Directional DNA Cloning Technology to Capture CDNA s. Application in the Construction of a Human Immune Antibody Phage-Display Library,”…
[cited by applicant]
Shalaby, M.R., et al., “Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene,” The Journal of Experimental Medicine 175(1):217-225, The…
[cited by applicant]
Shen, Z., et al., “Higher intratumoral inWltrated Foxp3+ Treg Nos. and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer,” J Cancer Res Clin Oncol 136(10):1585-9, Springer, Germany (Oc…
[cited by applicant]
Shi, L., et al., “De Novo Selection of High-affinity Antibodies From Synthetic Fab Libraries Displayed on Phage as Pix Fusion Proteins,” Journal of Molecular Biology, 397(2):385-396, Academic Press, United Kingdom (Mar.…
[cited by applicant]
Shields, R.L., et al., “High Resolution Mapping of the Binding Site on Human IgGI for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc gamma R,” The Journal …
[cited by applicant]
Shiraishi, M., et al., “Short-step Chemical Synthesis of Dna by Use of Mmtrs Group for Protection of 5′-hydroxyl Group,” Nucleic Acids Symposium Series, 51:129-130, Oxford University Press, United Kingdom (2007).
[cited by applicant]
Shopes, B., “A Genetically Engineered Human Igg Mutant With Enhanced Cytolytic Activity,” Journal of Immunology 148(9):2918-2922, American Association of Immunologists, United States (May 1992).
[cited by applicant]
Sidman, et al., “Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid,” Biopolymers 22:547-556, John Wiley & Sons, Inc., United States (Jan. 1983).
[cited by applicant]
Smith, T.F. and Waterman, M.S., “Comparison of Biosequences,” Advances in Applied Mathematics 2(4):482-489, Academic Press, Inc., United States (Dec. 1981).
[cited by applicant]
Soler, D., et al., “CCR8 Expression Identifies CD4 Memory T Cells Enriched for FOXP3+ Regulatory and Th2 Effector Lymphocytes,” J Immunol 177(10):6940-51, American Association of Immunologists, United States (Nov. 2006).
[cited by applicant]
Songsivilai, S. and Lachmann, P.J., “Bispecific Antibody: A Tool for Diagnosis and Treatment of Disease,” Clinical and Experimental Immunology 79(3):315-321, Blackwell Scientific Publications, United Kingdom (1990).
[cited by applicant]
Southern, P.J. and Berg, P., “Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter,” Journal of Molecular and Applied Genetics 1(4):327-341, Ra…
[cited by applicant]
Stahli, C., et al., “Distinction of Epitopes by Monoclonal Antibodies,” Methods in Enzymology 92:242-253, Academic Press, United States (1983).
[cited by applicant]
Steinberger, P., et al., “Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains ,”J Immunol 172(4):2352-9, American Association of Immunologists, United States (Feb. 2004).
[cited by applicant]
Subedi, G., et al., “The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor,” MAbs 8(8):1512-1524, Taylor & Francis, United Kingdom (May 2016).
[cited by applicant]
Suresh, M.R., et al., “Bispecific Monoclonal Antibodies from Hybrid Hybridomas,” Methods in Enzymology 121:210-228, Academic Press Inc., United States (1986).
[cited by applicant]
Tang, Y., et al., “Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen,” J Immunol 179(5):2815-23, American Association of Immunologists, United States (Sep. …
[cited by applicant]
Temming, A., et al., “Functional Attributes of Antibodies, Effector Cells, and Target Cells Affecting NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity,” J Immunol 203(12):3126-3135, American Association of Immu…
[cited by applicant]
Thyagarajan, H., et al., “CCR8 is expressed by post-positive selection CD4-lineage thymocytes but is dispensable for central tolerance induction,” PLoS One 13(7):e0200765, PLOS, United States (Jul. 2018).
[cited by applicant]
Todorovska, A., et al., “Design and Application of Diabodies, Triabodies and Tetrabodies for Cancer Targeting,” Journal of Immunological Methods 248(1-2):47-66, Elsevier, Netherlands (Feb. 2001).
[cited by applicant]
Topalian, S., et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” N Engl J Med 366(26):2443-54, Massachusetts Medical Society, United States (Jun. 2012).
[cited by applicant]
Tutt, A., et al., “Trispecific F(ab′)3 Derivatives That Use Cooperative Signaling via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells,” Journal of Immunology, 147:60-69, American Associati…
[cited by applicant]
Van Damme, H., et al., “Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy,” J Immunother Cancer 9(2):e001749, BMJ Publishing Group Ltd …
[cited by applicant]
Villarreal, D.O., et al., “Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer,” Cancer Research, 78(18):5340-5348, American Association for Cancer Research, Unite…
[cited by applicant]
Vinay, D., et al., “Immune evasion in cancer: Mechanistic basis and therapeutic Strategies,” Semin Cancer Biol 35 Suppl:S185-S198, Academic Press Inc., United States (Dec. 2015).
[cited by applicant]
Vogelpoel, L., et al., “Control of cytokine production by human Fc gamma receptors: implications for pathogen defense and autoimmunity,” Front Immunol 6:79, Frontiers Media S.A., Switzerland (Feb. 2015).
[cited by applicant]
Wang, L., et al., “Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer,” Nat Immunol 20(9):1220-1230, Springer, Germany (Sep. 2019).
[cited by applicant]
Wright, A., et al., “Antibody Variable Region Glycosylation: Position Effects on Antigen Binding and Carbohydrate Structure,” The EMBO Journal 10(10):2717-2723, Wiley Blackwell, England (1991).
[cited by applicant]
Wu, C., et al., “Simultaneous Targeting of Multiple Disease Mediators by a Dual-variable-domain Immunoglobulin,” Nature Biotechnology 25(11):1290-1297, Nature Publishing Co., United States (2007).
[cited by applicant]
Yang, Y., et al., “Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation,” Front Immunol 11:1371, Frontiers Media S.A., Switzerland (Jul. 2020).
[cited by applicant]
Yeung, Y.A., and Wittrup, D.K.,, “Quantitative Screening of Yeast Surface-displayed Polypeptide Libraries by Magnetic Bead Capture”, Biotechnology Progress 18(2):212-220, American Institute of Chemical Engineers, United…
[cited by applicant]
Yuan, Y., et al., “Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials,” Clin Cancer Res 22(17):4291-301, American Association for Cancer Research, United States (Sep. 2016).
[cited by applicant]
Zapata, G., et al., “Engineering Linear F(ab′)2 Fragments for Efficient Production in
[cited by applicant]
Zhou, H., et al., “Accuracy, Safety, and Reliability of Novel Phase I Trial Designs” Clin Cancer Res 24(18):4357-4364, American Association for Cancer Research, United States (Sep. 2018).
[cited by applicant]
Zhou, Y., et al., “BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials,” JCO Clin Cancer Inform 5:91-101, American Society of Clinical Oncology, United States (Jan. 2021).
[cited by applicant]
Zingoni, A., et al., “Cutting Edge: The Chemokine Receptor CCR8 Is Preferentially Expressed in Th2 But Not Th1 Cells,” J Immunol 161(2):547-51, American Association of Immunologists, United States (Jul. 1998).
[cited by applicant]
Wigler, M., et al., “Transformation of Mammalian Cells with Genes from Procaryotes and Eucaryotes,” Cell 16:777-785, Cell Press, United States (Apr. 1979).
[cited by applicant]
Shipman, L., “Interrogating intratumoral Treg cells,” Nature Reviews Immunology, 17:4-5, Springer, Germany (Dec. 2016).
[cited by applicant]
Anonymous, Product technical data sheet for Purified anti-human CD198 (CCR8) Antibody clone L263G8, BioLegend, Inc., United States, revised Oct. 9, 2013, 3 pages.
[cited by applicant]
Anonymous, Product technical data sheet for BV421 Mouse Anti-Human CCR8 (CD198) clone 433H data sheet, Becton, Dickinson and Company, United States, Feb. 2016, 2 pages.
[cited by applicant]
Anonymous, Product technical data sheet for Monoclonal Anti-Human CCR8-Fluorescein clone 191704, R&D Systems, Inc., United States, Oct. 2007, 2 pages.
[cited by applicant]
Zahavi, D., et al., “Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy” Antibody Therapeutics 1:7-12, Oxford University Press, United Kingdom (Jun. 2018).
[cited by applicant]
Nelson, A., “Antibody fragments: Hope and hype” mAbs, 2:77-83, Taylor & Francis, United Kingdom (Jan. 2010).
[cited by applicant]
Kipps, T., et al., “Importance of Immunoglobulin Isotype in Human Antibody-Dependent, Cell-Mediated Cytotoxicity Directed by Murine Monoclonal Antibodies” Journal of Experimental Medicine, 161:1-17 (Jan. 1985).
[cited by applicant]
Anonymous, “Immunoglobulin G Review ” InvivoGen, United States, 1 page (2011).
[cited by applicant]
Plitas, G., et al., “Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target” 76: Abstract P4-04-11, Proceedi…
[cited by applicant]
Mordant, P., et al., “Bioluminescent Orthotopic Mouse Models of Human Localized Non-Small Cell Lung Cancer: Feasibility and Identification of Circulating Tumour Cells” PLoS ONE, 6:e26073, PLOS, United States (Oct. 2011).
[cited by applicant]
Klages, K., et al., “Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma” Cancer research 70:7788-99, American Association for Cancer Research, United…
[cited by applicant]
Vargas, F., et al., “Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors” Immunity, 46:577-586, Cell Press, United States (Apr. 2017).
[cited by applicant]
Eruslanova, E., et al., “Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas,” Clin Cancer Res 19(7):1670-80, American Association for Cancer Research, United States (Ap…
[cited by applicant]
Das, S., et al., “Tumor cell entry into the lymph node is controlled by CCLI chemokine expressed by lymph node lymphatic sinuses,” J Exp Med 210(8):1509-28, Rockefeller University Press, United States (Jul. 2013).
[cited by applicant]
Plitas, G., et al., “Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer (Supplemental information),” Immunity 45(5):1122-1134, Cell Press, United States (Nov. 2016).
[cited by applicant]
De Simone, M., et al., “Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells (Supplemental Information),” Immunity 45(5):1135-1147, Cell Press, United States …
[cited by applicant]
Vela, M., et al., “Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges,” Front Immunol 6:12, Frontiers Media S.A., Switzerland (Jan. 2015).
[cited by applicant]
Ishii, T., et al., “Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma,” Clin Cancer Res 16(5):1520-31, American Association for Cancer Re…
[cited by applicant]
Kurose, K., et al., “Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients,” Clin Cancer Res 21(19):4327-36, American Association for Cancer Research, Uni…
[cited by applicant]
Shuptrine, C., et al., “Monoclonal antibodies for the treatment of cancer,” Semin Cancer Biol 22(1):3-13, Academic Press Inc., United States (Feb. 2012).
[cited by applicant]
Vashti, I., et al., “Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases” Mol Immunol 67:171-82, Pergamon Press, United Kingdom…
[cited by applicant]
Vashti, I., et al., “Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases (Annex A)” Mol Immunol 67:171-82, Pergamon Press, Unit…
[cited by applicant]
Anonymous, Product technical data sheet for Purified Anti-mMouse CD198 (CCR8) Antibody clone SA214G2, BioLegend, Inc., United States, revised Dec. 16, 2015, 3 pages.
[cited by applicant]